6 REASONS TO ADD THE PROPEL FAMILY OF IMPLANTS TO YOUR SINUS SURGERY ARMAMENTARIUM
Provides your sinus surgery patients with individualized treatment options1-3
- Intersect ENT has a complete portfolio of implants indicated for use following ESS
- Intersect ENT offers a family of 3 steroid-eluting implants under one brand: PROPEL
- The PROPEL family of steroid-eluting implants provides you with the flexibility to treat different sinus anatomies, including the ethmoid, maxillary, and frontal sinuses in a multitude of patient types
- PROPEL implants promote a tailored approach to postoperative care with options on implants’ indication, size, shape, and delivery system
- The PROPEL implant provides localized delivery of mometasone furoate (MF), minimizing the reliance of patient compliance
Breakthrough technology that opens the sinus cavity and delivers mometasone furoate1-3
- PROPEL implants feature an innovative 2-in-1 mechanism that opens the sinuses while delivering mometasone furoate, an advanced corticosteroid, directly where it is needed
- Mometasone furoate was selected for use in PROPEL implants for its optimal sinonasal drug characteristics: highly lipophilic, targeted and potent, and low systemic bioavailability
- PROPEL implants are composed of a bioabsorbable polymer that breaks down between 30-45 days so implant removal is not required
- PROPEL has a non-obstructive self-expanding design that allows for mucociliary clearance and the delivery of topical rinses
Delivers the power of robust, clinically proven benefits1-3
- The efficacy and safety profiles were established in over 350 patients enrolled across 6 clinical studies
- Proven in prospective randomized, blinded, intra-patient controlled trials to reduce
PROPEL
- the need for postoperative interventions
- the need for surgical interventions
- the need for oral steroids
- frank polyposis
- significant adhesions
- middle turbinate lateralization
- patients’ perceived burden of symptoms
PROPEL Mini
- the need for postoperative interventions
- the need for surgical interventions
- the need for oral steroids
- occlusion/restenosis
PROPEL Contour
- the need for postoperative interventions
- the need for surgical interventions
- occlusion/restenosis
- inflammation
- PROPEL in the ethmoid is proven to positively impact patients’ perceived burden of symptoms at 6 months
Proven success in the real world1-6
- With more than 7 years of real-world use and over 300,000 patients treated, the trusted performance of PROPEL family of implants provide patients with proven improvements in sinus surgery outcomes
- Supported by Level 1-A evidence to significantly improve outcomes of ethmoid sinus surgery
- First and only FDA-approved steroid-eluting sinus implant
- PMA-approved
- 15+ peer-reviewed publications
Efficacious regardless of disease severity4
PROPEL demonstrated efficacy across multiple patient types:
- With and without nasal polyps
- Undergoing primary and revision surgery
- Undergoing traditional and ballooning surgery
Intersect ENT partnership and collaboration
- One of the only companies specifically dedicated to innovation in the field of otolaryngology
- Dedicated to improving the quality of life for patients with ENT conditions providing robust clinical evidence
- Continued collaboration with physicians to innovate and transform CRS care
